Frank Mottola - 30 Oct 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Reporting relationship: SVP, Chief Tech. Ops. Officer
Issuer ticker: SUPN
Reported as of: 30 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Nov 2026, 16:15:57 UTC
Prior SEC filing: 14 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Timothy C. Dec, as attorney-in-fact

Filing notes and source

Key filing fact

Frank Mottola filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 02 Nov 2026.

Key facts

This page summarizes Frank Mottola's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Nov 2026, 16:15.

Change

Previous filing in this sequence was filed on 14 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001804567 Primary reporting owner

Mottola Frank

Relationship: SVP, Chief Tech. Ops. Officer
Address: C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Signature date: 02 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SUPN transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +100,000
Change %
Price: $0.000000^*
Shares after: 100,000
Date: 30 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $0.000000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in four installments. 40% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 15% of the RSUs vest upon the three-year anniversary of the Closing. 15% of the RSUs vest upon the four-year anniversary of the Closing.